Working adults and families concerned about weight management or prediabetes may also discuss these medications with their healthcare professionals to determine if they are appropriate for their specific needs and health goals
As we age or face heightened environmental exposure (think Torontos winter air pollution and harsh weather), glutathione levels naturally decrease, leading to dullness, uneven skin tone, and more pronounced signs of aging
It is part of a class of medications called GLP-1 receptor agonists, which work with natural hormones in the body
Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
For most healthy adults, the clinical trials at common doses do not demonstrate clear, proven harms, but the TMAO question remains an area of active research
Government-run insurance plans, like Medicare and Medicaid, typically don't cover weight-loss drugs